Stock comparison
Genmab A/S
Veeva Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.47B
Sector
Healthcare
VEEV
Veeva Systems
Market cap
$26.07B
Sector
Healthcare
Overall winner
Veeva Systems VEEV
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | VEEV | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 66B | VEEV |
| Benjamin Graham | 64C | 81A | VEEV |
| Philip Fisher | 48D | 77B | VEEV |
| Peter Lynch | 25F | 60C | VEEV |
| Joel Greenblatt | 76B | 52C | GMAB |
| Charlie Munger | 68C | 62C | GMAB |
| Terry Smith | 71C | 65D | GMAB |
Side-by-side metrics
| Metric | GMAB | VEEV |
|---|---|---|
| Market cap | $16.47B | $26.07B |
| P/E (TTM) | 6.2x | 28.7x |
| EV/EBIT | 12.0x | 26.9x |
| ROIC (TTM) | 43.78% | 9.48% |
| Gross margin | 93.88% | 75.53% |
| Net margin | 18.23% | 28.44% |
| Revenue CAGR 5y | -18.45% | 14.63% |
| EPS CAGR 5y | -23.48% | 18.76% |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 28.7x+79%
- ROIC (TTM)43.78%vs 9.48%+78%
- EV/EBIT12.0xvs 26.9x+55%
- Gross margin93.88%vs 75.53%+20%
VEEV leads on
- EPS CAGR 5y18.76%vs -23.48%+180%
- Revenue CAGR 5y14.63%vs -18.45%+179%
- Debt / Equity0.0xvs 0.1x+82%
- Market cap$26.07Bvs $16.47B+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.